Submission Guidelines

About the Journal

PLOS Medicine publishes original research articles of outstanding medical importance. We will consider manuscripts of any length; we encourage the submission of both substantial full-length bodies of work and shorter manuscripts that report novel findings that might be based on a more limited range of experiments.

The writing style should be concise and accessible, avoiding jargon so that the paper is understandable for readers outside a specialty or those whose first language is not English. Editors will make suggestions for how to achieve this, as well as suggestions for deletions or additions that could be made to the article to strengthen the argument. Our aim is to make the editorial process rigorous and consistent, but not intrusive or overbearing. Authors are encouraged to use their own voice and to decide how best to present their ideas, results, and conclusions. 

About the Submission Process

Format-free initial submission

PLOS Medicine uses the initial submission process, allowing authors to quickly submit to the journal and obtain rapid feedback from the editors. If the editors decide that the work is suitable for peer review, authors will be asked to provide a full submission with additional information.

Creating an initial submission is the most efficient way to obtain feedback from the journal. Authors who email with an inquiry will be asked to submit the manuscript as an initial submission.

Format-free full submission

If you receive an initial decision from the journal committing to peer review, you will be asked to complete a full submission with additional information including:

• Full author list and author details
• Details of the availability of data generated in the study
• Details of any ethical approvals
• Details of clinical trials registration, if applicable

Style and Format

Manuscript Organization

Most manuscripts should be organized as follows. Instructions for each element appear below.

• Title
• Authors
• Affiliations
• Abstract
• Introduction
• Methods (or Methods and Materials)
• Results
• Discussion
• Acknowledgments
• References
• Supporting information captions

Other elements

• Upon revision, figure files should be uploaded separately from the manuscript, and each figure caption should be inserted in read order after the first paragraph where the figure is cited. Read more information about our figure requirements during each stage of editorial review.
• Tables are inserted immediately after the first paragraph in which they are cited.
• Supporting information files are uploaded separately.

Parts of a Submission

Title

Include a full title and a short title for the manuscript.

Titles should be written in sentence case (only the first word of the text, proper nouns, and genus names are capitalized). Avoid specialist abbreviations if possible. For clinical trials, systematic reviews, or meta-analyses, the subtitle should include the study design.

Author list

Author contributions

You will enter all author contributions in the submission system if your manuscript is selected for peer review. Provide at minimum one contribution for each author, and use the CRediT taxonomy to describe each contribution. Read the policy and the full list of roles.

To qualify for authorship, all contributors must meet at least one of the seven core contributions (conceptualization, methodology, software, validation, formal analysis, investigation, data curation), as well as at least one of the writing contributions (original draft preparation, review and editing). Authors may also satisfy the other remaining contributions; however, these alone will not qualify them for authorship.

Contributions will be published with the final article, and they should accurately reflect contributions to the work. The submitting author is responsible for completing this information at full submission, and we expect that all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time.

Cover letter

Upload a cover letter as a separate file in the online system.

The cover letter should address the following questions:

• Why is this manuscript suitable for publication in PLOS Medicine?
• Why will your study inspire researchers or clinicians, and how will it improve patient care or public health, or drive the understanding of disease forward?

Title page

The title, authors, and affiliations should all be included on a title page as the first page of the manuscript file.  

  Download our sample title, author list, and affiliations page (PDF)

Abstract

The Abstract comes after the title page in the manuscript file. The abstract text is also entered in a separate field in the submission system.  

The research article Abstract is divided into the following three sections: Background, Methods and Findings, and Conclusions. It should contain all the following elements (items in square brackets are needed only for some study types).

PLOS Medicine prefers abstract submissions not exceed 300 words, with a maximum of 500 words allowed.

Background

• This section should clearly describe the rationale for the study. It should end with a statement of the specific study hypothesis and/or study objectives.

Methods and Findings

• Describe the study participants or what was studied (e.g., patient population, cell lines; be as specific as possible, including numbers of individuals studied). Describe the study design, intervention if applicable, main methods used, primary outcome measure(s), and length of follow up if applicable.
• [If appropriate, include how many participants were assessed out of those enrolled. For survey research, include the response rate.]
• [If critical to the understanding of the paper, describe how results were analyzed, i.e., which specific statistical tests were used.]
• Describe the main outcomes and quantify the results using a measure of precision (e.g., 95% confidence interval). Describe any adverse events.
• Describe the main limitations of the study.

Conclusions

• Provide a general interpretation of the results with any important recommendations for future research.
• [For a clinical trial, provide any trial identification number(s) and name(s) (e.g., trial registration number, protocol number or acronym).]

Introduction

The introduction should put the focus of the manuscript into a broader context. As you compose the Introduction, think of readers who are not experts in this field. Include a brief review of the key literature. If there are relevant controversies or disagreements in the field, they should be mentioned so that a non-expert reader can delve into these issues further. The Introduction should conclude with a brief statement of the overall aim of the experiments and a comment about whether that aim was achieved.

Methods

The Methods should provide enough detail for reproduction of the findings. Protocols for new methods should be included, but well-established methodological procedures may simply be referenced. A full description of the methods should be included in the manuscript itself rather than in a supplemental file.

Methods should also include a section with descriptions of any statistical methods used. The description should conform to the criteria outlined by the Uniform Requirements, as follows: 

Submit detailed protocols for newer or less established methods. Well-established protocols may simply be referenced. Protocol documents for clinical trials, observational studies, and other non-laboratory investigations may be uploaded as supporting information.

We recommend and encourage you to deposit laboratory protocols in protocols.io, where protocols can be assigned their own persistent digital object identifiers (DOIs).

To include a link to a protocol in your article:

1. Describe your step-by-step protocol on protocols.io
2. Select Get DOI to issue your protocol a persistent digital object identifier (DOI) 
3. Include the DOI link in the Methods section of your manuscript using the following format provided by protocols.io: http://dx.doi.org/10.17504/protocols.io.[PROTOCOL DOI]

At this stage, your protocol is only visible to those with the link. This allows editors and reviewers to consult your protocol when evaluating the manuscript. You can make your protocols public at any time by selecting Publish on the protocols.io site. Any referenced protocol(s) will automatically be made public when your article is published.

PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io articles. Read more information on Lab Protocol articles.

Results

The Results section should include all primary and secondary outcome measures analyzed. The section may be divided into subsections, each with a concise subheading. Tables and figures central to the study should be included in the main paper. The Results section should be written in past tense.

PLOS journals require authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception.

Large data sets, including raw data, may be deposited in an appropriate public repository. See our list of recommended repositories.

For smaller data sets and certain data types, authors may provide their data within Supporting Information files accompanying the manuscript. Authors should take care to maximize the accessibility and reusability of the data by selecting a file format from which data can be efficiently extracted (for example, spreadsheets or flat files should be provided rather than PDFs when providing tabulated data).

For more information on how best to provide data, read our policy on data availability. PLOS does not accept references to “data not shown.”

As outlined in the Uniform Requirements: 

Discussion

The Discussion should be concise and tightly argued. It should start with a brief summary of the main findings. It should include paragraphs on the generalizability, clinical relevance, strengths, and limitations of your study.

You may wish to discuss the following points also:

• How do the conclusions affect the existing knowledge in the field?
• How can future research build on these observations and what are the key experiments that must be done?

Acknowledgments

Those who contributed to the work but do not meet our authorship criteria should be listed in the Acknowledgments with a description of the contribution.

Authors are responsible for ensuring that anyone named in the Acknowledgments agrees to be named.

References

Any and all available works can be cited in the reference list. Acceptable sources include:

• Published or accepted manuscripts
• Manuscripts on preprint servers, providing the manuscript has a citable DOI or arXiv URL.

Do not cite the following sources in the reference list:

• Unavailable and unpublished work, including manuscripts that have been submitted but not yet accepted (e.g., “unpublished work,” “data not shown”). Instead, include those data as supplementary material or deposit the data in a publicly available database.
• Personal communications (these should be supported by a letter from the relevant authors but not included in the reference list)
• Submitted research should not rely upon retracted research. You should avoid citing retracted articles unless you need to discuss retracted work to provide historical context for your submitted research. If it is necessary to discuss retracted work, state the article’s retracted status in your article’s text and reference list.

Ensure that your reference list includes full and current bibliography details for every cited work at the time of your article’s submission (and publication, if accepted). If cited work is corrected, retracted, or marked with an expression of concern before your article is published, and if you feel it is appropriate to cite the work even in light of the post-publication notice, include in your manuscript citations and full references for both the affected article and the post-publication notice. Email the journal office if you have questions.

References are listed at the end of the manuscript and numbered in the order that they appear in the text. In the text, cite the reference number in square brackets (e.g., “We used the techniques developed by our colleagues [19] to analyze the data”). PLOS uses the numbered citation (citation-sequence) method and first six authors, et al.

Do not include citations in abstracts. 

Make sure the parts of the manuscript are in the correct order before ordering the citations.

​Formatting references

PLOS uses the reference style outlined by the International Committee of Medical Journal Editors (ICMJE), also referred to as the “Vancouver” style. Example formats are listed below. Additional examples are in the ICMJE sample references.

Journal name abbreviations should be those found in the National Center for Biotechnology Information (NCBI) databases. 

Supporting information

Authors can submit essential supporting files and multimedia files along with their manuscripts. All supporting information will be subject to peer review. All file types can be submitted, but files must be smaller than 20 MB in size.

Authors may use almost any description as the item name for a supporting information file as long as it contains an “S” and number. For example, “S1 Appendix” and “S2 Appendix,” “S1 Table” and “S2 Table,” and so forth.  

Supporting information files are published exactly as provided, and are not copyedited.

Supporting information captions

List supporting information captions at the end of the manuscript file. Do not submit captions in a separate file.

The file number and name are required in a caption, and we highly recommend including a one-line title as well. You may also include a legend in your caption, but it is not required.

In-text citations

We recommend that you cite supporting information in the manuscript text, but this is not a requirement. If you cite supporting information in the text, citations do not need to be in numerical order.

Figures and Tables

Figure files

If you are submitting an Initial or Full Submission and would prefer to embed each figure in the manuscript, do so in read order, immediately following the paragraph where the figure is first mentioned and above the related figure caption.

Upon revision, prepare and submit each figure as an individual file, removing all embedded figures.

Figure citations

Cite figures in ascending numeric order upon first appearance in the manuscript file.

Figure captions

Insert figure captions in the manuscript text, immediately following the paragraph where the figure is first cited (read order). Don’t include captions as part of the figure files themselves or submit them in a separate document.

At a minimum, include the following in your figure captions:

• A figure label with Arabic numerals, and “Figure” abbreviated to “Fig” (e.g. Fig 1, Fig 2, Fig 3, etc). Match the label of your figure with the name of the file uploaded at submission (e.g. a figure citation of “Fig 1” must refer to a figure file named “Fig1.tif”).
• A concise, descriptive title

The caption may also include a legend as needed.

Tables

Cite tables in ascending numeric order upon first appearance in the manuscript file.

Place each table in your manuscript file directly after the paragraph in which it is first cited (read order). Do not submit your tables in separate files.

Tables require a label (e.g., “Table 1”) and brief descriptive title to be placed above the table. Place legends, footnotes, and other text below the table. 

Data reporting

All data and related metadata underlying the findings reported in a submitted manuscript should be deposited in an appropriate public repository, unless already provided as part of the submitted article.

Repositories may be either subject-specific (where these exist) and accept specific types of structured data, or generalist repositories that accept multiple data types. We recommend that authors select repositories appropriate to their field. Repositories may be subject-specific (e.g., GenBank for sequences and PDB for structures), general, or institutional, as long as DOIs or accession numbers are provided and the data are at least as open as CC BY. Authors are encouraged to select repositories that meet accepted criteria as trustworthy digital repositories, such as criteria of the Centre for Research Libraries or Data Seal of Approval. Large, international databases are more likely to persist than small, local ones.

To support data sharing and author compliance of the PLOS data policy, we have integrated our submission process with a select set of data repositories. The list is neither representative nor exhaustive of the suitable repositories available to authors. Current repository integration partners include Dryad and FlowRepository. Please contact data@plos.org to make recommendations for further partnerships.

Instructions for PLOS submissions with data deposited in an integration partner repository:

• Deposit data in the integrated repository of choice.
• Once deposition is final and complete, the repository will provide you with a dataset DOI (provisional) and private URL for reviewers to gain access to the data.
• Enter the given data DOI into the full Data Availability Statement, which is requested in the Additional Information section of the PLOS Full Submission form. Then provide the URL passcode in the Attach Files section.

If you have any questions, please email us.

Accession numbers

All appropriate data sets, images, and information should be deposited in an appropriate public repository. See our list of recommended repositories.

Accession numbers (and version numbers, if appropriate) should be provided in the Data Availability Statement. Accession numbers or a citation to the DOI should also be provided when the data set is mentioned within the manuscript.

In some cases authors may not be able to obtain accession numbers of DOIs until the manuscript is accepted; in these cases, the authors must provide these numbers at acceptance. In all other cases, these numbers must be provided at full submission.

Identifiers

As much as possible, please provide accession numbers or identifiers for all entities such as genes, proteins, mutants, diseases, etc., for which there is an entry in a public database, for example:

• Ensembl
• Entrez Gene
• FlyBase
• InterPro
• Mouse Genome Database (MGD)
• Online Mendelian Inheritance in Man (OMIM)
• PubChem

Identifiers should be provided in parentheses after the entity on first use.

Additional Information Requested at Submission

Financial Disclosure Statement

This information should describe sources of funding that have supported the work. If your manuscript is published, your statement will appear in the Funding section of the article.

Include your statement in the Financial Disclosure section of the initial submission form.

The statement should include:

• Specific grant numbers
• Initials of authors who received each award
• URLs to sponsors’ websites

Also state whether any sponsors or funders (other than the named authors) played any role in:

• Study design
• Data collection and analysis
• Decision to publish
• Preparation of the manuscript

If they had no role in the research, include this sentence: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

If the study was unfunded, include this sentence as the Financial Disclosure statement: “The author(s) received no specific funding for this work."

Competing interests

This section should list specific competing interests associated with any of the authors. If authors declare that no competing interests exist, the article will include a statement to this effect.

All authors will be contacted by email at submission of the full paper to declare whether they have any financial, personal or professional interests that could be construed to have influenced their paper. Any relevant competing interests of authors must be available to editors and reviewers during the review process and will be stated in published articles.

Related manuscripts

When submitting a manuscript, all authors are asked to indicate that they do not have a related or duplicate manuscript under consideration (or accepted) for publication elsewhere. If related work has been or will be submitted elsewhere or is in press elsewhere, then a copy must be uploaded with the article submitted to PLOS. Reviewers will be asked to comment on the overlap between related submissions.

Preprints

PLOS encourages authors to post preprints to accelerate the dissemination of research. Posting a manuscript on a preprint server does not impact consideration of the manuscript at any PLOS journal.

Authors posting on bioRxiv or medRxiv can choose to concurrently submit their manuscripts to relevant PLOS journals through the direct transfer service.

Authors submitting manuscripts in the health sciences to PLOS Medicine may choose to have PLOS forward their submission to medRxiv for consideration for posting as a preprint.

Guidelines for Specific Study Types

Study design, reporting, and analyses are assessed against all relevant research and methodological technique standards held by the community. Guidelines for specific study types are outlined below.

Authors must check the EQUATOR Network site for any reporting guidelines that apply to the particular study design and ensure they include any required supporting information recommended by the relevant guidelines.

Documentation for specific studies should be uploaded as supporting information during manuscript submission. When referencing parts of the manuscript in these documents, please quote section or paragraph numbers rather than page numbers, as page numbers in your submission may not match those of the published manuscript.

Human and animal research

All research involving humans and animals must have been approved by the authors' institutional review board or equivalent committee(s), and that board must be named by the authors in the manuscript.

For research involving human participants, informed consent must have been obtained or the reason for lack of consent explained, and all clinical investigations must have been conducted according to the principles expressed in the Declaration of Helsinki. The Methods section of the paper must state whether informed consent was written or oral. If informed consent was oral, it must be stated in the paper: (a) why written consent could not be obtained, (b) that the IRB approved the use of oral consent, and (c) how oral consent was documented.

Authors may be required to submit, on request, a statement from the research ethics committee or institutional review board indicating approval of the research. We also encourage authors to submit a sample of a patient consent form, and may require submission in particular instances.

For studies involving humans categorized by race/ethnicity, age, disease/disabilities, religion, sex/gender, sexual orientation, or other socially constructed groupings, authors should, as much as possible,

• make explicit their methods of categorizing human populations;
• define categories in as much detail as the study protocol allows;
• justify their choices of definitions and categories, including for example whether any rules of human categorization were required by their funding agency;
• explain whether (and if so, how) they controlled for confounding variables such as socioeconomic status, nutrition, environmental exposures, etc.

In addition, outmoded terms and potentially stigmatizing labels should be changed to more current, acceptable terminology. For example, “white” should be used rather than “Caucasian” and “patients with cancer” should be used rather than “cancer patients” or “cancer victims”.

PLOS Medicine publishes few animal studies but will consider animal studies of two kinds:

1. Translational studies that establish a novel explanatory mechanism for a significant clinical problem, to an extent that will directly inform specific clinical approaches. Such papers must include or refer to human data that is sufficiently compelling to establish clinical relevance of the animal model.
2. Models relevant to the treatment or prevention of major health problems, in which the interventions cannot be tested in humans for ethical reasons, but will provide compelling justification for specific changes in the design of subsequent clinical trials.

All animal work must have been conducted according to relevant national and international guidelines. In addition, PLOS Medicine requires that animal research follows the ARRIVE guidelines. In accordance with the recommendations of the Weatherall report, The use of non-human primates in research, we specifically require authors to include details of animal welfare and steps taken to ameliorate suffering in all work involving non-human primates. The institution that approved the study must be named, and it must be stated in the paper that the study was conducted adhering to the institution's guidelines for animal husbandry.

Clinical trials

PLOS follows the World Health Organization’s (WHO) definition of a clinical trial:

Registering Clinical Trials

All clinical trials submitted to PLOS journals must be entered in a publicly accessible registry approved by the WHO or ICMJE. See the list of approved registries.

PLOS journals consider prospective trial registration (that is, registration before participant enrollment has begun) to be best publication practice, as recommended by the ICMJE. Clinical trials that began to enroll participants before ICMJE recommendations took effect on July 1, 2005 may be retrospectively registered.

More information about trial registration, including the WHO definition of a clinical trial, is in the ICMJE FAQ.    

PLOS Medicine is unlikely to publish clinical trials that are not prospectively registered. We recognize, however, that in rare cases late registration may occur for exceptional reasons that merit consideration. Authors seeking evaluation by PLOS Medicine of a non–prospectively registered clinical trial must provide a compelling reason for lack of prospective registration.

In addition, as for all PLOS journals, authors wishing to submit a clinical trial that was not publicly registered before participant enrollment began must register the trial retrospectively in a publicly accessible registry. They must also:

• Register all related clinical trials and confirm they have done so in the Methods section
• Explain in the Methods the specific reasons for failing to register before participant enrollment
• Confirm that future trials will be registered prospectively

PLOS journal editors may decline to further consider any clinical trial for which, in the editor’s judgment, absence of prospective registration raises concerns of selective publication or selective reporting of research outcomes. 

PLOS supports the public disclosure of all clinical trial results, as mandated, for example, by the 2007 FDA Amendments Act. Prior disclosure of results on a clinical trial registry site will not affect consideration.

Required Documentation

Clinical trial reports must adhere to the relevant reporting guidelines for their study design, such as CONSORT for randomized controlled trials, TREND for non-randomized trials, and other specialized guidelines as appropriate.

For all clinical trial submissions, authors must include the following:

• Registration details (reported in the Methods section and in the submission form)
• CONSORT checklist or relevant reporting guideline (uploaded as supporting information)
• CONSORT flow diagram (uploaded as Fig 1)
• Trial protocol (uploaded as supporting information)
• Details of prior approval for human subjects research by an institutional review board (IRB) or equivalent ethics committee(s)

The submission will not be considered if documentation is not provided. The checklist, flow diagram, and protocol will be published with the article if the manuscript is accepted.

The manuscript file must include the following information:

• An explanation of any deviation from the trial protocol
• Description of informed consent obtained from participants
• Any information on statistical methods or participants not indicated in the CONSORT documentation

Systematic reviews and meta-analyses

Reports of systematic reviews and meta-analyses must adhere to the PRISMA Statement or alternative guidelines appropriate to the study design, and include the completed checklist and flow diagram to accompany the main text. Authors must complete the appropriate reporting checklist not only with page references, but also with sufficient text excerpted from the manuscript to explain how they accomplished all applicable items.

Abstracts should follow PRISMA for Abstracts, using the PLOS abstract format. Authors must also state within the Methods section of their paper whether a protocol exists for their systematic review, and if so, provide a copy of the protocol as supporting information.

The journal supports the prospective registration of systematic reviews. Authors whose systematic review was prospectively registered (e.g., in a registry such as PROSPERO) should provide the registry number in their abstract. Registry details and protocols will be made available to editors and reviewers, and included with the paper if the report is ultimately published.

PLOS Medicine does not publish narrative reviews except as part of invited Collections

Diagnostic studies

Reports of studies of diagnostic accuracy must adhere to the STARD requirements or alternative guidelines appropriate to the study design (see the EQUATOR web site) and include a completed checklist as supporting information. Authors must complete the appropriate reporting checklist not only with page references, but also with sufficient text excerpted from the manuscript to explain how they addressed all applicable items.

Observational studies

For observational studies, including case control, cohort, and cross-sectional studies, authors must adhere to the STROBE Statement or alternative guidelines appropriate to the study design (see the EQUATOR web site) and include a completed checklist as supporting information. Authors must complete the appropriate reporting checklist not only with page references, but also with sufficient text excerpted from the manuscript to explain how they addressed all applicable items.

For observational studies, authors are required to clearly specify (a) What specific hypotheses the researchers intended to test, and the analytical methods by which they planned to test them; (b) What analyses they actually performed; and (c) When reported analyses differ from those that were planned, authors must provide transparent explanations for differences that affect the reliability of the study's results.

If a prospective analysis plan (from the study's funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing an observational study, authors must include the relevant prospectively written document with the manuscript submission for access by editors and reviewers and eventual publication alongside the accepted paper. If no prospectively written document exists, authors should explain how and when they determined the analyses being reported.

Microarray experiments

Reports of microarray experiments must conform to the MIAME guidelines, and the data from the experiments must be deposited in a publicly accessible database.

Biological and biomedical research

We recommend authors refer to the BioSharing Portal for prescriptive checklists for reporting biological and biomedical research where applicable.

Animal studies

Studies including animals must follow the ARRIVE guidelines and include a completed ARRIVE Checklist as supporting information. Authors must complete the appropriate reporting checklist not only with page references, but also with sufficient text excerpted from the manuscript to explain how they addressed all applicable items.

Small and macromolecule crystal data

Manuscripts reporting new and unpublished three-dimensional structures must include sufficient supporting data and detailed descriptions of the methodologies used to allow the reproduction and validation of the structures. All novel structures must have been deposited in a community endorsed database prior to submission (please see our list of recommended repositories).

Small molecule single crystal data

Authors reporting X-Ray crystallographic structures of small organic, metal-organic, and inorganic molecules must deposit their data with the Cambridge Crystallographic Data Centre (CCDC), the Inorganic Crystal Structure Database (ICSD), or similar community databases providing a recognized validation functionality. Authors are also required to include the relevant structure reference numbers within the main text (e.g. the CCDC ID number), as well as the crystallographic information files (.cif format) as Supplementary Information, along with the checkCIF validation reports that can be obtained via the International Union of Crystallography (IUCr).

Macromolecular structures

Authors reporting novel macromolecular structures must have deposited their data prior to initial submission with the Worldwide Protein Data Bank (wwPDB), the Biological Magnetic Resonance Data Bank (BMRB), the Electron Microscopy Data Bank (EMDB), or other community databases providing a recognized validation functionality. Authors must include the structure reference numbers within the main text and submit as Supplementary Information the official validation reports from these databases.

Other Article Types

If you are submitting content other than a research article, read the guidelines for other article types.

PLOS Community Action Publishing (CAP) – non member fee support

PLOS Medicine no longer has APCs, and instead is funded by a new collective action model called PLOS Community Action Publishing (CAP). Institutions pay to become community members so their authors are not subject to fees. Corresponding and contributing authors from non-member institutions are subject to non-member fees.

To find out if your institution is a PLOS Medicine CAP member, please visit our institutional partner page and search by your institutional name or by the agreement type “Community Action Publishing.”

If the corresponding author’s institution is a member, they will be notified at acceptance that no fees are required. If the corresponding author’s instution is not a member, they will be subject to a non-member fee. If the non-member corresponding author’s coauthors belong to member institutions, there is a 25% discount on the non-member fee. Be sure to check if your contributing authors’ institutions are members to take advantage of this discount.